JP2012523243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523243A5 JP2012523243A5 JP2012505149A JP2012505149A JP2012523243A5 JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5 JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012505149 A JP2012505149 A JP 2012505149A JP 2012523243 A5 JP2012523243 A5 JP 2012523243A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- tumor
- stem cell
- cytotoxic protein
- coding region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16878709P | 2009-04-13 | 2009-04-13 | |
| US61/168,787 | 2009-04-13 | ||
| PCT/EP2010/054844 WO2010119039A1 (en) | 2009-04-13 | 2010-04-13 | Engineered mesenchymal stem cells and method of using same to treat tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523243A JP2012523243A (ja) | 2012-10-04 |
| JP2012523243A5 true JP2012523243A5 (https=) | 2013-05-23 |
| JP5727458B2 JP5727458B2 (ja) | 2015-06-03 |
Family
ID=42270435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505149A Active JP5727458B2 (ja) | 2009-04-13 | 2010-04-13 | 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9434925B2 (https=) |
| EP (1) | EP2419113B1 (https=) |
| JP (1) | JP5727458B2 (https=) |
| KR (1) | KR20120088542A (https=) |
| CN (1) | CN102695517B (https=) |
| AU (1) | AU2010237130B2 (https=) |
| BR (1) | BRPI1013771A2 (https=) |
| CA (1) | CA2758120C (https=) |
| IL (1) | IL215581A0 (https=) |
| RU (1) | RU2539099C2 (https=) |
| SG (1) | SG175127A1 (https=) |
| WO (1) | WO2010119039A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
| JP2015506697A (ja) * | 2012-02-01 | 2015-03-05 | ポステック アカデミー‐インダストリー ファウンデーション | １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤 |
| US20130203166A1 (en) * | 2012-02-06 | 2013-08-08 | Protobios Llc | Stimulation of multipotency of mesenchymal stem cells by chemokine ccl5 |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| US20140065110A1 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of California | Genetically modified msc and therapeutic methods |
| MX377561B (es) * | 2012-11-05 | 2025-03-10 | Regeneron Pharma | Animales no humanos genéticamente modificados y métodos de uso de los mismos. |
| US10472647B2 (en) | 2012-12-21 | 2019-11-12 | The Administrators Of The Tulane Educational Fund | Primary mesenchymal stem cells as a vaccine platform |
| WO2015100268A1 (en) * | 2013-12-23 | 2015-07-02 | The Regents Of The University Of California | Mesenchymal stem cells for targeted cancer therapy |
| JP2017506884A (ja) * | 2014-01-17 | 2017-03-16 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 活性薬の送達を増強するための方法 |
| WO2016026854A2 (en) | 2014-08-18 | 2016-02-25 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| AU2015335607B2 (en) * | 2014-10-24 | 2020-04-23 | Calidi Biotherapeutics (Nevada), Inc. | Combination immunotherapy approach for treatment of cancer |
| CN104622903B (zh) * | 2015-01-20 | 2018-10-09 | 奥思达干细胞有限公司 | 抗恶性黑色素瘤的干细胞制剂及其制备方法 |
| WO2016118780A1 (en) | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2016138340A1 (en) * | 2015-02-27 | 2016-09-01 | Saint Louis University | Tumor suppressor sall1 as a therapeutic agent for treating cancer |
| ES2750008T3 (es) * | 2015-02-27 | 2020-03-24 | Apceth Gmbh & Co Kg | Células madre mesenquimatosas modificadas genéticamente que expresan klotho |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| CN108135996B (zh) | 2015-08-11 | 2022-06-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| WO2017036925A1 (en) * | 2015-08-28 | 2017-03-09 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells for the treatment of metastatic liver disease |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3462883B1 (en) | 2016-06-07 | 2023-08-16 | The Pacific Heart, Lung,&Blood Institute | Compositions and their use in treating cancer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| KR20190109389A (ko) | 2016-11-03 | 2019-09-25 | 엑소스템 바이오텍 리미티드 | 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도 |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| WO2018191619A1 (en) | 2017-04-13 | 2018-10-18 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| WO2019195142A1 (en) | 2018-04-03 | 2019-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Mesenchymal stem cells comprising a chimeric antigen receptor (car) for treating inflammatory and autoimmune diseases |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| CA3103423A1 (en) * | 2018-06-14 | 2019-12-19 | Loma Linda University | Engineered hematopoietic stem cells for the treatment of acute myeloid leukemia |
| AU2019359890B2 (en) | 2018-10-17 | 2024-10-24 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| WO2020172515A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents |
| SG10201902002SA (en) * | 2019-03-06 | 2020-10-29 | Nat Univ Singapore | Non-viral modification of mesenchymal stem cells |
| EP4556072A3 (en) * | 2019-08-23 | 2025-06-11 | Orbsen Therapeutics Limited | Compositions for monocyte and macrophage polarization and methods of use |
| EP3995130A1 (en) | 2020-11-06 | 2022-05-11 | JunctuCell Biomed Manufacturing GmbH | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| AU2021375735A1 (en) | 2020-11-06 | 2023-06-08 | Aatec Medical Gmbh | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6265564B1 (en) * | 1996-08-02 | 2001-07-24 | Regeneron Pharmaceuticals, Inc. | Expressed ligand-vascular intercellular signalling molecule |
| US7098185B2 (en) * | 1998-05-18 | 2006-08-29 | University College London | Polypeptide hormone phosphatonin |
| US20060057553A1 (en) * | 2000-05-30 | 2006-03-16 | Estuardo Aguilar-Cordova | Chimeric viral vectors for gene therapy |
| WO2002069953A1 (en) * | 2001-03-01 | 2002-09-12 | The Board Of Regents Of The University Of Texas System | Methods of treating lung inflammation |
| US20030165579A1 (en) * | 2002-02-27 | 2003-09-04 | Chih-Hui Lin | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers |
| EP1544213B1 (en) * | 2003-12-19 | 2008-02-20 | Charité - Universitätsmedizin Berlin | Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases |
| JP2006194752A (ja) * | 2005-01-14 | 2006-07-27 | Sumitomo Metal Mining Co Ltd | Ｘ線回折測定における試料固定方法および試料固定具 |
| KR101022401B1 (ko) * | 2005-09-29 | 2011-03-15 | 아주대학교산학협력단 | 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물 |
| WO2008150368A1 (en) | 2007-05-24 | 2008-12-11 | Apceth Gmbh & Co. Kg | Cd34 stem cell-related methods and compositions |
-
2010
- 2010-04-13 RU RU2011146048/10A patent/RU2539099C2/ru not_active IP Right Cessation
- 2010-04-13 CA CA2758120A patent/CA2758120C/en not_active Expired - Fee Related
- 2010-04-13 EP EP10713933.9A patent/EP2419113B1/en not_active Not-in-force
- 2010-04-13 CN CN201080026333.1A patent/CN102695517B/zh not_active Expired - Fee Related
- 2010-04-13 JP JP2012505149A patent/JP5727458B2/ja active Active
- 2010-04-13 WO PCT/EP2010/054844 patent/WO2010119039A1/en not_active Ceased
- 2010-04-13 SG SG2011073418A patent/SG175127A1/en unknown
- 2010-04-13 US US13/264,084 patent/US9434925B2/en not_active Expired - Fee Related
- 2010-04-13 BR BRPI1013771A patent/BRPI1013771A2/pt not_active IP Right Cessation
- 2010-04-13 KR KR1020117026918A patent/KR20120088542A/ko not_active Ceased
- 2010-04-13 AU AU2010237130A patent/AU2010237130B2/en not_active Ceased
-
2011
- 2011-10-06 IL IL215581A patent/IL215581A0/en unknown
-
2016
- 2016-08-31 US US15/253,353 patent/US20170015976A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012523243A5 (https=) | ||
| RU2011146048A (ru) | Сконструированные мезенхимальные стволовые клетки и способ их применения для лечения опухолей | |
| JP2010528008A5 (https=) | ||
| Howells et al. | Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer | |
| Deng et al. | Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9 | |
| Power et al. | Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer | |
| Shi et al. | Engineered mesenchymal stem/stromal cells against cancer | |
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| JP2012010710A5 (https=) | ||
| CA2640528A1 (en) | Oncolytic adenoviruses for cancer treatment | |
| Feng et al. | Stabilization of G-quadruplex DNA and inhibition of Bcl-2 expression by a pyridostatin analog | |
| Hughes et al. | Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus | |
| Cao et al. | Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter | |
| Bilsland et al. | Virotherapy: cancer gene therapy at last? | |
| Lucas et al. | Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer | |
| CN101565718A (zh) | 三靶向嵌合型溶瘤腺病毒Ad5/F11载体的构建方法及其应用 | |
| Xiao et al. | Oncolytic viruses: advanced strategies in cancer therapy | |
| Shen et al. | Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene | |
| Yoon et al. | A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth | |
| Hemminki | From molecular changes to customised therapy | |
| Sakai et al. | Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer | |
| WO2022107705A1 (ja) | 新規遺伝子組換えワクシニアウイルス及びその利用 | |
| Asavarut et al. | Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma | |
| RU2814581C1 (ru) | Генетический вектор Ad6/3-hTERT-GMCSF, содержащий геномные последовательности рекомбинантного аденовируса 6 серотипа, промотор теломеразы человека, ген гранулоцитарно-макрофагального колониестимулирующего фактора человека, а также ген белка файбер со встройкой домена fiber knob аденовируса 3 серотипа, обладающий повышенной трансдукцией в опухолевые клетки | |
| Tagawa et al. | Cancer therapy with local oncolysis and topical cytokine secretion |